drugset / Trial / NCT05095168

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects

NCT05095168 ↗

Phase 1 Completed 31 enrolled CARE Pharma Shanghai Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106 injection.

Timeline

Start
2021-02-22
Primary completion
2021-11-30
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject OMOPRUBART Monoclonal antibody — Intravenous